USP releases compendium of quality standards for compounded medicines.
The United States Pharmacopeia Convention (USP) has published the USP Compounding Compendium to provide easy access to quality related standards for compounded medicines. The compendium gives compounding practitioners access to all compounding-related general chapters from the United States Pharmacopeia–National Formulary (USP–NF) and features more than 40 supporting general chapters and more than 170 compounding preparation monographs. It also includes the USP–NF General Notices and Requirements, “which provide definitions and important information necessary to correctly interpret and apply compounding standards.”
“USP has a deep historic connection to the practice of pharmacy, stretching back to the very beginning of our origination nearly 200 years ago when practitioners regularly prepared medicines as-needed,” noted USP Chief Executive Officer Ronald T. Piervincenzi, PhD, in a press release. “Our founders, most of whom practiced and taught medicine and/or pharmacy, promoted quality standards as a tool to advance their profession and improve public health, and USP’s commitment to those core ideals continues today.”
The USP Compounding Compendium will be updated with the release of each new USP–NF edition and supplement. Subscribers can access and download all updates during their 12-month subscription period. USP has partnered with the International Academy of Compounding Pharmacists (IACP) and the National Community Pharmacy Association (NCPA) to enable their members to purchase the USP Compounding Compendium directly through the IACP and NCPA websites.
Source: USP.org
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.